Analyst initiated coverage on Haemonetics with a new price target
$HAE
Medical/Dental Instruments
Health Care
Analyst initiated coverage of Haemonetics with a rating of Overweight and set a new price target of $116.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/6/2024 | $116.00 | Overweight | Analyst |
| 11/8/2024 | $120.00 | Outperform → Strong Buy | Raymond James |
| 9/13/2024 | $116.00 | Buy | CL King |
| 9/11/2024 | $85.00 | Neutral | BofA Securities |
| 9/10/2024 | $112.00 | Buy | BTIG Research |
| 6/12/2024 | $112.00 | Hold → Buy | Needham |
| 10/13/2022 | $90.00 | Buy | Mizuho |
| 2/9/2022 | $70.00 → $66.00 | Outperform | Raymond James |
8-K - HAEMONETICS CORP (0000313143) (Filer)
8-K - HAEMONETICS CORP (0000313143) (Filer)
8-K - HAEMONETICS CORP (0000313143) (Filer)
BOSTON, Jan. 14, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has completed the previously announced sale of its whole blood assets to GVS, S.p.A ("GVS"), one of the world's leading manufacturers of filter solutions for applications in the healthcare and life sciences sectors. In connection with the closing of this transaction, GVS has acquired Haemonetics' portfolio of proprietary whole blood collection, processing and filtration solutions, along with Haemonetics' manufacturing facility in Covina, California where certain of these prod
BOSTON, Jan. 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish third quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, February 6, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 6, 2025. The call can be accessed via teleconference at: Q3 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the cal
BOSTON, Jan. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that Chris Simon, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 5:15 pm Pacific Time. The public may access Mr. Simon's presentation live via audio webcast at: https://jpmorgan.metameetings.net/events/healthcare25/sessions/58190-haemonetics-corporation/webcast?gpu_only=true&kiosk=true The live webcast can also be accessed under the Events & Presentations section of Haemonetics' Investor Relations website. The
Analyst initiated coverage of Haemonetics with a rating of Overweight and set a new price target of $116.00
Raymond James upgraded Haemonetics from Outperform to Strong Buy and set a new price target of $120.00
CL King initiated coverage of Haemonetics with a rating of Buy and set a new price target of $116.00
SC 13G - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
BOSTON, Jan. 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish third quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, February 6, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 6, 2025. The call can be accessed via teleconference at: Q3 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the cal
Financial release accessible online BOSTON, Nov. 7, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its second quarter fiscal year 2025, which ended September 28, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on November 7, 2024. The conference call and webcast can be accessed with the following information: Teleconference link: https://register.vevent.com/register/BI3c9f473811f94
BOSTON, Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 7, 2024. The call can be accessed via teleconference at: Q2 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the ca
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ
BOSTON, Oct. 4, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced the appointment of Roy Galvin as President, Global Plasma and Blood Center, effective October 10, 2022. He will report to Chris Simon, Haemonetics' President and Chief Executive Officer. As President of Haemonetics' Global Plasma and Blood Center business units, Galvin will have responsibility for driving the Company's transformational growth objectives and advancing the